Professor Mark Britnell

Chair of Health Innovation Manchester

Professor Mark Britnell joined Health Innovation Manchester as its new chair in September 2024, joining the board of senior leaders to accelerate world-leading innovation to improve the lives of Greater Manchester’s 2.8m population. Mark brings his vast experience of global public and private health systems across 81 countries, having led organisations at local, regional and national levels.

Mark, who is originally from Chester, has dedicated all his 35 years of professional experience to the development of healthcare around the world, working in 81 countries. He was vice chair of KPMG UK until the end of December 2022 and before that was Global Chairman and Senior Partner for Healthcare, Government and Infrastructure at KPMG International.  

In 2000, Mark was appointed Chief Executive of University Hospitals Birmingham, where he masterminded the largest new hospital build in NHS history, and later went on to run the NHS South Central region before joining the NHS management board as Director General at the Department of Health, including leading the national NHS innovation strategy at the time.  

He is a Trustee of The King’s Fund, a professor at the Global Business School for Health at University College London and an adjunct professor at the Rotman School of Management, University of Toronto. 

Professor Ben Bridgewater

Chief Executive, Health Innovation Manchester

Professor Ben Bridgewater is Chief Executive of Health Innovation Manchester, an academic health science system that brings together health, academia and industry. The mission is to accelerate innovation into practice at pace and scale, so to transform the lives of Greater Manchester’s 2.8 million citizens.

He is a leading expert on health informatics, national clinical audit, clinical governance, healthcare transparency, patient experience measurement and digital transformation in healthcare, publishing numerous high profile academic outputs and delivering innovative IT tools for disseminating clinical outcomes to professionals and the public.

Prior to joining Health Innovation Manchester, Ben worked for global technology company DXC Technology as the Director of the Healthcare and Lifesciences Global Build Advisory Team. Until January 2016, he was a cardiac surgeon at the University Hospital of South Manchester for nearly 18 years.

Ben also provided clinical leadership for the UK national cardiac audit programme, as well as leading analyses that provides UK hospital and cardiac surgery mortality rates to the public. The programme is world-leading and associated with a 50% reduction in risk-adjusted mortality over 10 years.

Dr Helen Routh

Non-Executive Director

Dr. Helen Routh is a board director, advisor and senior executive with more than 25 years’ healthcare technology experience in business management, strategy and innovation. She currently works with public and private companies and clinical groups focused on the use of data to drive new solutions, business models and outcome improvements.

As well as being a non-executive director at Health Innovation Manchester, Dr Routh is currently non-executive Chair of Ultromics, and non-executive Director of Agfa Gevaert N.V. She is also an advisor to Nina Capital.

Previously, Helen held senior business and functional roles at Philips, leading teams in the Americas, Europe and Asia, working with multi-billion businesses and new ventures. Her responsibilities included Philips corporate research in North America, Senior VP and General Manager of the global clinical informatics businesses, and Senior VP Strategy and Innovation working across all the professional and consumer health businesses at Philips.

Dr Mark Chakravarty

Non-Executive Director

Dr Mark Chakravarty was appointed non-executive director at Health Innovation Manchester in January 2023.

Mark is a business leader and physician with more 20 years’ international leadership experience in both the private and public sector, including Novartis, Procter and Gamble and the NHS. He has worked in a variety of roles, including medical, scientific, external relations and communications.

Mark is currently the Vice Chair of the unitary board of directors at National Institute of Health and Care Excellence (NICE). He was formerly the global head of communications and patient advocacy for Novartis Pharmaceuticals, and also led communications for the feminine and family care sector at Procter & Gamble.

Professor Steven Myint

Non-Executive Director

Professor Steven Myint was appointed non-executive director at Health Innovation Manchester in January 2023.

Steven has considerable entrepreneurial experience, and has been the founder of several companies across biotech, medtech, diagnostics, AI and corporate culture. He has been a board level executive in Biotech and Pharmaceutical multinational companies, including a Medical Director for Global Research and Development at GSK Global, and Senior Vice-President for R&D and Chief Medical Officer at BTG International. Amongst other current roles, he is chairman of Inex Private Ltd, and non-executive director of Aplagon Oy and Medisapiens Oy.

Steven was a former Dean of Medicine & Head of health schools at the University of Surrey Head of Microbiology at the University of Leicester. An NHS consultant for many years, Professor Myint has also been National Clinical Lead in AMR/Diagnostics for the Department of Health and Social Care (DHSC) and the NHS England and NHS Improvement (NHS E&I), and Senior Independent Director for Mid-Essex Hospitals NHS Trust. He is currently Co-chairman of the External Advisory Network for the Royal College of Surgeons of England.

In addition, Steven is the former executive director of the European Federation of Neurological Associations, the ambassador and founder of ethical values organisations, and a member of research funding panels in UK, Singapore and Finland.

Steve Oldfield CB

Non-Executive Director

Steve Oldfield CB was appointed non-executive director at Health Innovation Manchester in February 2023.

Steve has international leadership experience across the private and public sector, in healthcare and life sciences. He was appointed Chief Commercial Officer at the Department of Health and Social Care in 2017, where he worked at the centre of healthcare policy & operations throughout Brexit and COVID-19. Steve was awarded a Companion of the Order of the Bath (CB) in 2021 in recognition of his work on the COVID 19 response

Steve was formerly Chief Operating Officer for PGT Healthcare, a consumer-health joint venture between Procter & Gamble and Teva, and UK Managing Director for the Sanofi Group. He has strong record of delivery against ambitious targets and has successfully led major organisation transformation initiatives.

Steve was previously a non-executive director at Genomics England Ltd, and a member of the Advisory Board of Healthcare UK. He was the Chair of EU Medicines Group (EMG), UK Government Medicines Access Group (MAG) and Metrics Oversight Group (MOG), He was also an ABPI Board member, and a member of the UK NHS Industry Council & Accelerated Access Group.

Sir Richard Leese

Chair, Greater Manchester Integrated Care Board

Sir Richard Leese was appointed as Chair of Greater Manchester Integrated Care Board from 1^st November, 2021. Until December 1^st, 2021 he had been Leader of Manchester City Council since 1996.

Richard’s interests include devolution, place-based budgets and the links between economic development and social policy; public service reform as the route to tackling social determinants and inequality; developing open democracy and the community leadership role of local authorities; and the role of cities in creating a sustainable future.

His involvement in Health and Care goes back over two decades to when he chaired the Manchester/Salford/Trafford Health Action Zone. He chaired Manchester’s Health and Well-Being Board from its inception, and was the GMCA Health portfolio holder for Greater Manchester, chairing the GM Health and Care Board.

To be confirmed

To be confirmed

Dr Owen Williams OBE

Northern Care Alliance NHS Foundation Trust, Group Chief Executive

Dr Owen Williams is Chief Executive of the NCA FT since November 2021. Prior to this appointment, he was Chief Executive of Calderdale and Huddersfield NHS Foundation Trust (CHFT), a position which he has held since 2012. In 2020 he was granted the degree of Doctor of Business Administration by the University of Huddersfield following the successful completion of his thesis which commenced 6 years previously in 2014. In the 2019 New Year’s Honours list he was awarded an OBE for service to health care across West Yorkshire and was asked to lead a National piece of work across the NHS in England with regards to reducing Health Inequalities. He was previously Vice Chair of the NHS Confederation and prior to joining the NHS he has worked across Local Government including two roles as Chief Executive at Calderdale Metropolitan Borough Council and Rossendale District Borough Council. Before working in the Public Sector, he worked in commercial business including his first employment at the Yorkshire Building Society. He is passionate about reducing health inequality and ensuring that no communities – regardless of race, colour or creed – get left behind.

Professor Nic Beech

Vice-Chancellor of The University of Salford

Professor Nic is the Vice-Chancellor of the University of Salford and was previously Vice-Principal at the University of St Andrews, Provost of Dundee University and Vice-Chancellor of Middlesex University. He is Chair of the Quality Council for UK Higher Education, a Commissioner on the International Higher Education Commission and Treasurer and on the Board of Universities UK. He was previously Treasurer and on the Board of the Academy of Social Sciences and Chair of Access HE.  Nic is currently a member of the DfE Curriculum and Assessment Review panel.

Nic’s academic field is business and management and his research focused on identity, change and educational leadership. His awards from Learned Societies include, at a national level, the Lifetime Achievement in Research Award and at an international level, the Exceptional Service to the Field of Management Worldwide Award. He was the longest-serving president of the British Academy of Management and was the 2023 recipient of the British Academy of Management lifetime achievement award.

Mark Cubbon

Chief Executive, Manchester University NHS Foundation Trust

Mark Cubbon is Group Chief Executive of Manchester University NHS Foundation Trust since April 2023 and has worked in the NHS for his entire career.  He joined the NHS as a nurse in Greater Manchester in 1992.

Prior to his role in Manchester University NHS Foundation Trust, he was Chief Delivery Officer for NHS England.

Mark has held a range of senior leadership roles in his career, including Chief Executive at Portsmouth Hospitals University NHS Trust, regional Chief Operating Officer for NHS Improvement in the Midlands and East of England, and several director roles in London NHS trusts, including Moorfields Eye Hospital, Whipps Cross and Barts Health.

Professor Duncan Ivison

President and Vice Chancellor of The University of Manchester

Professor Duncan Ivison, FAHA FRSN, is President and Vice-Chancellor of The University of Manchester. He holds degrees from McGill University and the London School of Economics. With over 20 years at the University of Sydney, Duncan has extensive experience in academic leadership, including roles as Dean and Deputy Vice Chancellor. A distinguished political and moral philosopher, he’s received numerous awards and held visiting positions at prestigious institutions worldwide. Duncan is passionate about public engagement and building partnerships between universities, communities, industry, and governments.

Caroline Simpson

Chief Executive, Greater Manchester Combined Authority

Dr Andrew Allen, M.D., Ph.D.

Non-Executive Director

Dr Andrew Allen, M.D., Ph.D. is an entrepreneur and global leader in biopharmaceuticals.

He co-founded Gritstone bio, a company developing next-generation vaccines for cancer and infectious disease, and has served as President, CEO and a board member since 2015. In 2009, Dr. Allen co-founded Clovis Oncology and served as Chief Medical Officer until 2015, and prior he was Chief Medical Officer at Pharmion Corporation. Dr. Allen also served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company.

He currently serves on the board of directors of TCR2 Therapeutics and Sierra Oncology (both public biopharma companies) and Revitope Oncology and Verge Genomics (both private biopharma companies). He previously served on the board of directors of Epizyme and Cell Design Labs (acquired by Gilead Sciences in 2017).

Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College of Science, Technology and Medicine in London.

Roger Spencer

Chief Executive, The Christie NHS Foundation Trust

Roger Spencer is Chief Executive at The Christie, having previously worked as Interim Chief Executive and Chief Operating Officer.

Roger has managed significant service developments including satellite radiotherapy & chemotherapy centres across Greater Manchester, transforming delivery of Christie services to an outpatient model. He directed the establishment of Christie partnerships for pharmacy, pathology, specialist diagnostic services and private patients & our academic investment plan. Roger leads for Greater Manchester in the National Cancer Vanguard developing & testing new models of care. In 2016 Roger led the Trust to a CQC Outstanding rating and is in the top 15 chief executives ranked by the HSJ in 2017. Roger leads the Christie in delivering the first national Proton Therapy service in the UK, operational in 2018.

Roger holds an MBA, an honours degree in Nursing Studies, is a Registered Nurse and is an independent director of Southway Housing Trust.

Roger previously worked at Salford Royal, East Lancashire Hospitals & Greater Manchester SHA.

Mark Fisher

Chief Executive, NHS Greater Manchester Integrated Care

Mark Fisher is Chief Executive of NHS Greater Manchester Integrated Care

Mark grew up in the West Country. He joined the Civil Service as a fast stream trainee in 1983. From June 2017 until June 2022 he was a Director General in the Cabinet Office and Secretary to the Grenfell Tower Public Inquiry. Since 1st July 2022, he has been Chief Executive of NHS Greater Manchester Integrated Care.

Mark has worked in the Benefits Agency, as HR Director of the (then) Department for Social Security, and as deputy Chief Executive of Jobcentre Plus. He has been Chief Executive of the Sector Skills Development Agency, promoting employer investment in skills, and Labour Market Director in the DWP during the 2009 recession. Immediately prior to his appointment to the Grenfell Tower Inquiry he was Director of the Office for Civil Society at the Cabinet Office (and later DCMS) with responsibility for social action, social investment, support for charities, business partnerships and youth policy.

Mark has been a Director of Working Links (Employment) Ltd, an advisor for the Prince’s Trust Team (formerly volunteers) programme, and a Public Member of Network Rail. He is Chair of the Estates and Finance Committee at Huddersfield University, and a Trustee of the Clore Social Leadership Foundation. He is also Chair of the Civil Service Sports Council (CSSC). In January 2010, Mr Fisher received a CBE.

Mark lives in Holmfirth, West Yorkshire.